Gain Therapeutics (GANX) Director Gwen Melincoff Receives Award

What Happened
Gwen A. Melincoff, a director of Gain Therapeutics, was granted a derivative award covering 25,000 shares on July 15, 2026. The award shows an acquisition price of $0.00 (no cash paid) and is reported as a derivative grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-15; Form 4 filed: 2026-07-17 (filed within the typical two-business-day window).
• Security: derivative award covering 25,000 shares; reported price: $0.00.
• Shares owned after transaction: not reported in the provided filing data.
• Footnote: the option vests in 12 equal monthly installments commencing July 24, 2026, subject to continuous service through each vesting date.
• No exercise, sale, or tax withholding reported in this filing.

Context
This appears to be a time-vesting option/award granted as director compensation. Such grants are common and do not represent an immediate market purchase or sale; value is realized only as awards vest (and if options are exercised or shares sold). The filing was timely and does not by itself indicate the director buying or selling stock on the open market.